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C
ancer is one of the most 
common causes of death 
worldwide. Lung cancer is 
the leading cause of cancer-related 
death worldwide [1], with a ﬁ  ve-
year survival rate of 10% in Europe 
and 15% in the United States [2,3]. 
Strikingly, for lung cancers detected 
in their early stage, the rate of 
recurrence within ﬁ  ve years is less than 
50%. When detected early, current 
therapies often cure common cancers, 
including those of the lung, breast, 
colon, rectum, stomach, and prostate 
[4]. Therefore, the development of 
reliable, noninvasive, and cost-effective 
early detection methods for common 
cancers is a priority of translational 
cancer research. Theoretically, a single 
method that detects multiple common 
cancer types at an early stage would 
have the biggest payoff for cancer 
control. 
The Ups and Downs of DNA 
Methylation in Cancer
Biomarkers of cancer cells have been 
derived from the genetic mutations 
and epigenetic alterations, such as 
DNA methylation, that together 
transform normal cells into tumors. 
DNA methylation involves the addition 
of a methyl group to sites where 
cytosine is followed by guanine along 
the DNA (i.e., a CpG dinucleotide, 
with p indicating the phosphate 
backbone that connects the cytosine 
and guanine nucleotides), and is 
essential for chromosome stability, 
maintenance of gene expression 
states, and proper telomere length in 
normal cells [5]. In primary human 
tumors, however, DNA methylation 
patterns are severely disrupted. This 
disruption includes aberrant gain of 
DNA methylation at CpG islands (short 
stretches of DNA with an abundance 
of CpG dinucleotides, located in 
gene regulatory regions) and loss 
of methylation in single copy and 
repetitive sequences. While CpG island 
methylation is associated with gene 
silencing, hypomethylation can result 
in gene activation and chromosomal 
instability [6]. 
The subset of CpG islands subjected 
to aberrant methylation in primary 
human tumors is non-random, due 
in part to selection of gene silencing 
events that favor unregulated cell 
growth, and also due to intrinsic 
sequence properties that may 
underlie gene-speciﬁ  c susceptibility to 
methylation [7–10]. One hypothesis 
is that alterations in DNA methylation 
play a key role in tumor initiation, and 
if this is true, methylation markers are 
ideally suited for detecting cancer in 
the early stages [11,12].
In contrast to tumor type–speciﬁ  c 
methylation markers, pan-cancer 
methylation markers could detect 
a far greater number of early stage 
cancers. Initial results of a prospective 
study of such markers are encouraging 
[13]. Belinsky and colleagues used 
aberrant methylation in a six-gene 
panel to detect lung cancer in sputum 
samples taken months to years prior 
to the clinical onset of cancer [13]. 
Other bodily ﬂ  uids are similarly useful 
for detection of noninvasive cancer 
via methylation markers, such as 
urine for kidney, bladder, or prostate 
cancer, and serum or nipple aspirates 
for breast cancer [14,15]. Notably, 
the panels of aberrantly methylated 
genes in these different tumor types 
overlap signiﬁ  cantly, indicating that 
assays for pan-cancer methylation 
markers are already available for 
testing. The important role of aberrant 
methylation in cancer detection and 
prognostication has been established on 
a small proportion of the CpG island–
containing genes. Thus, there remains a 
potentially vast, untapped resource for 
cancer-speciﬁ  c methylation biomarkers.
A New Study of Pan-Cancer 
Methylation Markers
In a new study published in PLoS 
Medicine, Shames et al. aim for a big 
payoff by searching genome-wide 
for CpG island methylation markers 
characteristic of not just one type of 
cancer, but common to several cancers 
of epithelial origin [16]. Identiﬁ  cation 
of such markers could facilitate 
detection and diagnosis, and might 
also shed light on molecular pathways 
that are characteristic of tumorigenesis 
in general, potentially providing new 
clinically relevant therapeutic targets 
with more widespread application. 
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Shames and colleagues began the 
quest for a pan-cancer marker by gene 
expression proﬁ  ling of non-small cell 
lung cancer cell lines before and after 
treatment with the DNA methylation 
inhibitor 5-aza-2′-deoxycytidine. Their 
initial goal was to ﬁ  nd genes expressed 
in a normal cell from which the tumor 
might arise, namely human bronchial 
epithelial cells, but silenced in the 
cancer cell lines and reactivated by 
inhibition of DNA methylation. The 
initial experiment netted 132 tumor-
speciﬁ  c candidates. Winnowing this 
gene subset to a manageable 45 genes 
involved random selection, and was 
followed by validation of gene silencing 
in primary lung tumors relative to the 
tumor-free adjacent lung. 
The eight most frequently 
methylated genes obtained from the 
lung cancer data were then tested 
in a set of 109 tumors from breast, 
colon, and prostate. Four genes, BCN1, 
MSX1, CCNA1, and ALDH1A3, showed 
extensive DNA methylation in all four 
epithelial cancers. In particular, BNC1 
and MSX1 were highly sensitive and 
speciﬁ  c for tumor detection. 
The authors concluded that key 
pathways altered epigenetically in 
the tumorigenic process may be 
shared across cancers of epithelial cell 
origin, despite obvious differences 
in their tissue source. This ﬁ  nding is 
of importance, since it highlights the 
possibility of identifying a common 
epigenetic denominator acting across 
tumor types, and perhaps underlying 
malignant transformation in general. 
However, we must again consider 
that these genes may be susceptible 
to aberrant DNA methylation, which 
could be due in part to their primary 
DNA sequence. Thus, it remains to 
be determined if the high frequency 
of DNA methylation observed in the 
BCN1, MSX1, CCNA1, and ALDH1A3 
genes stems from a functional need 
to abrogate expression and thus 
contribute to tumor initiation and/
or progression, from an intrinsic 
susceptibility of these loci to aberrant 
DNA methylation, or both. In either 
case, their utility as markers of cancer 
cells will be unaffected. 
Cautions and Clinical Implications
One hazard of using DNA methylation 
as a marker of cancer is the distinct 
possibility of false positives. The 
perfect marker would detect all cancer 
cases (100% sensitivity) and would 
not mistake normal cells for cancer 
cells (100% speciﬁ  city). However, the 
inﬂ  uence of ageing, diet, or hormones 
on DNA methylation may confound 
results if even a minor fraction of 
normal cells are methylated at the gene 
of interest in cancer-free individuals. 
This cautionary note has been sounded 
by Shames and colleagues [16] and 
by others [17]. The problem is that 
an assay sufﬁ  ciently sensitive to detect 
a rare cancer cell in blood or bodily 
ﬂ  uids could be particularly susceptible 
to this pitfall. Nevertheless, developing 
a single routine test for major cancer 
types in at-risk or asymptomatic 
individuals, paired with follow-up tests 
for speciﬁ  c malignancies, is a goal of 
high priority.
Efforts toward the perfect universal 
DNA methylation marker for early 
detection of tumors are well underway 
in research laboratories worldwide. 
Epigenetics researchers from Asia, 
Europe, and the US are joining forces 
to map the entire epigenome of normal 
and cancer cells [18]. Assays are 
currently available to detect aberrant 
DNA methylation in samples such as 
sputum, blood, feces, urine, and nipple 
aspirates, which can be procured via 
minimally invasive procedures and are 
likely to contain tumor cells and tumor 
DNA shed from a primary tumor mass 
[14,15]. 
Research endeavors such as these 
of Shames et al. are pivotal for the 
ﬁ  rst phase of identiﬁ  cation of suitable 
markers. Technological advances, 
such as the development of DNA 
methylation arrays, will undoubtedly 
aid in the methylation marker discovery 
phase. The next phase will include 
testing markers retrospectively and 
then prospectively in clinical settings, 
in a high-throughput and cost-effective 
manner. Coupling the discovery of 
new DNA methylation markers with 
investigation into their functional 
relevance will beneﬁ  t early detection 
efforts and improve our understanding 
of the tumorigenic process. 
Currently recommended methods 
for early detection of cancer include 
spiral computed tomography for 
patients at risk for lung cancer, breast 
exams and mammography for breast 
cancer detection, fecal occult blood 
tests and colonoscopy for colon cancer, 
and endoscopy for gastric cancers. 
However, several of these methods 
are expensive, prohibiting large-scale 
population-based use. It remains to be 
seen whether the new suite of DNA 
methylation markers from Shames 
et al. or those from prior studies will 
be true pan-cancer markers, and 
most importantly, whether they will 
outperform existing methods for early 
detection.  
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